Home›Trial›NCT04675333
🔬NCT04675333Phase 2ACTIVE NOT RECRUITING

Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

Study Summary

A Phase 2 Study of evorpacept (ALX148) in Combination With pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma.

Conditions
Head and Neck CancerHead and Neck Squamous Cell Carcinoma
Interventions / Drugs
evorpaceptpembrolizumabCisplatin/Carboplatin; 5FU
View on ClinicalTrials.gov ↗
Sponsor
ALXO
ALX Oncology
Oncology
D36/100
Study Details
Enrollment172 participants
Primary Completion—
Lead SponsorALX Oncology Inc.
Data Retrieved2026-04-11 02:53:29.486970+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.